Educational guide
Rapid discovery of cyclic peptide protein aggregation ...
Chiti, F. & Dobson, C. M. Protein misfolding, amyloid formation, and human disease: a summary of progress over the last decade. Annu. Rev. Biochem. 86 , 27–68 (2017). Article CAS PubMed Google Scholar Eisele, Y. S. et al. Targeting protein aggregation for the
This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.
Chiti, F. & Dobson, C. M. Protein misfolding, amyloid formation, and human disease: a summary of progress over the last decade. Annu. Rev. Biochem. 86, 27–68 (2017).
Eisele, Y. S. et al. Targeting protein aggregation for the treatment of degenerative diseases. Nat. Rev. Drug Discov. 14, 759–780 (2015).
Cawood, E. E., Karamanos, T. K., Wilson, A. J. & Radford, S. E. Visualizing and trapping transient oligomers in amyloid assembly pathways. Biophys. Chem. 268, 106505 (2021).
Saunders, J. C. et al. An in vivo platform for identifying inhibitors of protein aggregation. Nat. Chem. Biol. 12, 94–101 (2016).
Sárkány, Z., Rocha, F., Damas, A. M., Macedo-Ribeiro, S. & Martins, P. M. Chemical kinetic strategies for high-throughput screening of protein aggregation modulators. Chem. Asian J. 14, 500–508 (2019).
Xu, Y. et al. Tuning the rate of aggregation of hIAPP into amyloid using small-molecule modulators of assembly. Nat. Commun. 13, 1040 (2022).
Doig, A. J. et al. Why is research on amyloid-β failing to give new drugs for Alzheimer’s disease? ACS Chem. Neurosci. 8, 1435–1437 (2017).
Nie, Q., Du, X. & Geng, M. Small molecule inhibitors of amyloid β peptide aggregation as a potential therapeutic strategy for Alzheimer’s disease. Acta Pharmacol. Sin. 32, 545–551 (2011).
Zorzi, A., Deyle, K. & Heinis, C. Cyclic peptide therapeutics: past, present and future. Curr. Opin. Chem. Biol. 38, 24–29 (2017).
Zhang, H. & Chen, S. Cyclic peptide drugs approved in the last two decades (2001–2021). RSC Chem. Biol. 3, 18–31 (2022).
Naylor, M. R., Bockus, A. T., Blanco, M.-J. & Lokey, R. S. Cyclic peptide natural products chart the frontier of oral bioavailability in the pursuit of undruggable targets. Curr. Opin. Chem. Biol. 38, 141–147 (2017).
Li, X., Craven, T. W. & Levine, P. M. Cyclic peptide screening methods for preclinical drug discovery: miniperspective. J. Med. Chem. 65, 11913–11926 (2022).
Sohrabi, C., Foster, A. & Tavassoli, A. Methods for generating and screening libraries of genetically encoded cyclic peptides in drug discovery. Nat. Rev. Chem. 4, 90–101 (2020).
Huang, Y., Wiedmann, M. M. & Suga, H. RNA display methods for the discovery of bioactive macrocycles. Chem. Rev. 119, 10360–10391 (2018).
Scott, C. P., Abel-Santos, E., Wall, M., Wahnon, D. C. & Benkovic, S. J. Production of cyclic peptides and proteins in vivo. Proc. Natl Acad. Sci. USA 96, 13638–13643 (1999).
Yang, X. et al. A lanthipeptide library used to identify a protein–protein interaction inhibitor. Nat. Chem. Biol. 14, 375–380 (2018).
King, A. M. et al. Selection for constrained peptides that bind to a single target protein. Nat. Commun. 12, 6343 (2021).
Iannuzzelli, J. A. & Fasan, R. Expanded toolbox for directing the biosynthesis of macrocyclic peptides in bacterial cells. Chem. Sci. 11, 6202–6208 (2020).
Kritzer, J. A. et al. Rapid selection of cyclic peptides that reduce α-synuclein toxicity in yeast and animal models. Nat. Chem. Biol. 5, 655–663 (2009).
Delivoria, D. C. et al. Bacterial production and direct functional screening of expanded molecular libraries for discovering inhibitors of protein aggregation. Sci. Adv. 5, eaax5108 (2019).
Matis, I. et al. An integrated bacterial system for the discovery of chemical rescuers of disease-associated protein misfolding. Nat. Biomed. Eng. 1, 838–852 (2017).
Packer, M. S. & Liu, D. R. Methods for the directed evolution of proteins. Nat. Rev. Genet. 16, 379–394 (2015).
Esvelt, K. M., Carlson, J. C. & Liu, D. R. A system for the continuous directed evolution of biomolecules. Nature 472, 499–503 (2011).
Roth, T. B., Woolston, B. M., Stephanopoulos, G. & Liu, D. R. Phage-assisted evolution of Bacillus methanolicus methanol dehydrogenase 2. ACS Synth. Biol. 8, 796–806 (2019).
Brödel, A. K., Jaramillo, A. & Isalan, M. Engineering orthogonal dual transcription factors for multi-input synthetic promoters. Nat. Commun. 7, 13858 (2016).
Dewey, J. A., Azizi, S.-A., Lu, V. & Dickinson, B. C. A system for the evolution of protein–protein interaction inducers. ACS Synth. Biol. 10, 2096–2110 (2021).
Miller, S. M., Wang, T. & Liu, D. R. Phage-assisted continuous and non-continuous evolution. Nat. Protoc. 15, 4101–4127 (2020).
Zinkus-Boltz, J., DeValk, C. & Dickinson, B. C. A phage-assisted continuous selection approach for deep mutational scanning of protein-protein interactions. ACS Chem. Biol. 14, 2757–2767 (2019).
Cheruvara, H., Allen-Baume, V. L., Kad, N. M. & Mason, J. M. Intracellular screening of a peptide library to derive a potent peptide inhibitor of α-synuclein aggregation. J. Biol. Chem. 290, 7426–7435 (2015).
Lee, L. L., Ha, H., Chang, Y.-T. & DeLisa, M. P. Discovery of amyloid-β aggregation inhibitors using an engineered assay for intracellular protein folding and solubility. Protein Sci. 18, 277–286 (2009).
Wang, T., Badran, A. H., Huang, T. P. & Liu, D. R. Continuous directed evolution of proteins with improved soluble expression. Nat. Chem. Biol. 14, 972–980 (2018).
Wurth, C., Guimard, N. K. & Hecht, M. H. Mutations that reduce aggregation of the Alzheimer’s Aβ42 peptide: an unbiased search for the sequence determinants of Aβ amyloidogenesis. J. Mol. Biol. 319, 1279–1290 (2002).
Hubbard, B. P. et al. Continuous directed evolution of DNA-binding proteins to improve TALEN specificity. Nat. Methods 12, 939–942 (2015).
Thuronyi, B. W. et al. Continuous evolution of base editors with expanded target compatibility and improved activity. Nat. Biotechnol. 37, 1070–1079 (2019).
Tavassoli, A. et al. Inhibition of HIV budding by a genetically selected cyclic peptide targeting the Gag–TSG101 interaction. ACS Chem. Biol. 3, 757–764 (2008).
Miranda, E. et al. A cyclic peptide inhibitor of HIF-1 heterodimerization that inhibits hypoxia signaling in cancer cells. J. Am. Chem. Soc. 135, 10418–10425 (2013).
Badran, A. H. & Liu, D. R. Development of potent in vivo mutagenesis plasmids with broad mutational spectra. Nat. Commun. 6, 8425 (2015).
Milardi, D. et al. Proteostasis of islet amyloid polypeptide: a molecular perspective of risk factors and protective strategies for type II diabetes. Chem. Rev. 121, 1845–1893 (2021).
Spanopoulou, A. et al. Designed macrocyclic peptides as nanomolar amyloid inhibitors based on minimal recognition elements. Angew. Chem. Int. Ed. Engl. 130, 14711–14716 (2018).
Krotee, P. et al. Common fibrillar spines of amyloid-β and human islet amyloid polypeptide revealed by microelectron diffraction and structure-based inhibitors. J. Biol. Chem. 293, 2888–2902 (2018).
Horswill, A. R., Savinov, S. N. & Benkovic, S. J. A systematic method for identifying small-molecule modulators of protein–protein interactions. Proc. Natl Acad. Sci. USA 101, 15591–15596 (2004).
Carlson, J. C., Badran, A. H., Guggiana-Nilo, D. A. & Liu, D. R. Negative selection and stringency modulation in phage-assisted continuous evolution. Nat. Chem. Biol. 10, 216–222 (2014).
Buchanan, L. E. et al. Mechanism of IAPP amyloid fibril formation involves an intermediate with a transient β-sheet. Proc. Natl Acad. Sci. USA 110, 19285–19290 (2013).
Sivanesam, K. et al. Peptide Inhibitors of the amyloidogenesis of IAPP: verification of the hairpin-binding geometry hypothesis. FEBS Lett. 590, 2575–2583 (2016).
Mao, Y. et al. New peptide inhibitors modulate the self-assembly of islet amyloid polypeptide residues 11–20 in vitro. Eur. J. Pharmacol. 804, 102–110 (2017).
Wang, C. K. & Craik, D. J. Cyclic peptide oral bioavailability: lessons from the past. Pept. Sci. 106, 901–909 (2016).
Shah, N. H., Dann, G. P., Vila-Perelló, M., Liu, Z. & Muir, T. W. Ultrafast protein splicing is common among cyanobacterial split inteins: implications for protein engineering. J. Am. Chem. Soc. 134, 11338–11341 (2012).
Townend, J. E. & Tavassoli, A. Traceless production of cyclic peptide libraries in E. coli. ACS Chem. Biol. 11, 1624–1630 (2016).
Pu, J., Zinkus-Boltz, J. & Dickinson, B. C. Evolution of a split RNA polymerase as a versatile biosensor platform. Nat. Chem. Biol. 13, 432–438 (2017).
Hu, J. H. et al. Evolved Cas9 variants with broad PAM compatibility and high DNA specificity. Nature 556, 57–63 (2018).
Miller, S. M. et al. Continuous evolution of SpCas9 variants compatible with non-G PAMs. Nat. Biotechnol. 38, 471–481 (2020).
Gade Malmos, K. et al. ThT 101: a primer on the use of thioflavin T to investigate amyloid formation. Amyloid 24, 1–16 (2017).